RANK-Fc: a therapeutic antagonist for RANK-L in myeloma (Q35053943)

6 August 2017

1 reference

title

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma (English)

1 reference

6 August 2017

1

Emilia Mia Sordillo

1 reference

6 August 2017

Roger Niles Pearse

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

3 Suppl

1 reference

6 August 2017

page(s)

802-812

1 reference

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

The role of bisphosphonates for the treatment of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

Cellular Kinetics, Staging, and Immunoglobulin Synthesis in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Plasma-cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes: the POEMS syndrome. Distinctive radiographic abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Pathogenesis and management of bone lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Biology of osteoclast activation in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Human bone marrow myeloma cells express RANKL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

RANK is essential for osteoclast and lymph node development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

ASK1 is essential for JNK/SAPK activation by TRAF2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

B lymphopoiesis: global factors, local control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Bisphosphonates--mechanisms of action in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11134

7 January 2021

Identifiers

DOI

10.1002/CNCR.11134

1 reference

6 August 2017

1 reference